In chronic myeloid leukaemia (CML), Bcr-Abl enhances the phosphorylation stability of Emi1, thereby preventing the degradation of SKP2 and promoting the proliferation of CML cells [12]. Here, FBXO5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.